- Home
- SLG vs APLS Comparison
SLG vs APLS Comparison
Compare SLG & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLG | APLS |
|---|---|---|
| Founded | 1980 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.7B |
| IPO Year | 1997 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SLG | APLS |
|---|---|---|
| Price | $48.73 | $20.00 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 17 | 20 |
| Target Price | ★ $55.24 | $33.58 |
| AVG Volume (30 Days) | 1.1M | ★ 2.8M |
| Earning Date | 01-28-2026 | 02-27-2026 |
| Dividend Yield | ★ 6.36% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.36 |
| Revenue | $661,814,000.00 | ★ $1,016,397,000.00 |
| Revenue This Year | N/A | $28.88 |
| Revenue Next Year | $7.17 | N/A |
| P/E Ratio | ★ N/A | $55.68 |
| Revenue Growth | N/A | ★ 42.11 |
| 52 Week Low | $40.26 | $16.10 |
| 52 Week High | $68.14 | $31.17 |
Technical Indicators
Market Signals| Indicator | SLG | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 58.59 | 34.80 |
| Support Level | $47.43 | $20.03 |
| Resistance Level | $49.85 | $27.46 |
| Average True Range (ATR) | 1.53 | 1.43 |
| MACD | 0.23 | -0.74 |
| Stochastic Oscillator | 74.46 | 3.05 |
Price Performance
Historical ComparisonAbout SLG SL Green Realty Corp
SL Green Realty is one of the largest Manhattan property owners and landlords, with interest in around 32 million square feet of wholly owned and joint-venture office space. The company has additional property exposure through its limited portfolio of well-located retail space. It operates as a real estate investment trust.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.